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1. INTRODUCTION {#cas14100-sec-0001}
===============

Thyroid hormone regulates essential metabolic pathways in various tissues both during development and in postnatal life.[1](#cas14100-bib-0001){ref-type="ref"} Thyroid hormone plays regulatory roles in intestinal homeostasis as well by controlling expression of its target genes involved in intestinal metabolism or in turnover of the intestinal stem cells.[2](#cas14100-bib-0002){ref-type="ref"}, [3](#cas14100-bib-0003){ref-type="ref"} Thyroid hormone is also implicated in the development of various malignancies[4](#cas14100-bib-0004){ref-type="ref"} and epidemiologic studies indicate protective roles of TH signaling in CRC. Thyroid hormone replacement therapy in hypothyroidism patients was shown to reduce their relative risk of CRC.[5](#cas14100-bib-0005){ref-type="ref"}, [6](#cas14100-bib-0006){ref-type="ref"}, [7](#cas14100-bib-0007){ref-type="ref"} However, hyperthyroidism patients suffer from an increased risk of CRC.[7](#cas14100-bib-0007){ref-type="ref"} Studies using cell lines and animal models suggest opposing roles of TH receptors α and β (TRα and TRβ, encoded by *THRA* and *THRB*, respectively) in CRC. Specifically, while TRα1 enhances intestinal carcinogenesis by positively regulating Wnt signaling,[2](#cas14100-bib-0002){ref-type="ref"}, [8](#cas14100-bib-0008){ref-type="ref"}, [9](#cas14100-bib-0009){ref-type="ref"} TRβ1 expression is selectively lost upon malignant progression of CRC cells.[10](#cas14100-bib-0010){ref-type="ref"}, [11](#cas14100-bib-0011){ref-type="ref"} The precise roles of TH signaling in CRC development thus remain elusive.

Thyroid hormone contains iodine atoms and its hormonal activity is tightly regulated by the 3 iodothyronine deiodinases in the body[12](#cas14100-bib-0012){ref-type="ref"} (Figure [1](#cas14100-fig-0001){ref-type="fig"}A). In brief, DIO1 and DIO2 are TH‐activating enzymes that convert the prohormone thyroxine (T4) in circulation to the active hormone triiodothyronine (T3) in peripheral tissues. T3 binds effectively to TH receptors and initiates TH signaling at target tissues. Iodothyronine deiodinase 3 inactivates T3 and terminates its effects. Iodothyronine deiodinase 2 is expressed in multiple tissues, whereas DIO1 expression is virtually restricted to the liver and kidney.[13](#cas14100-bib-0013){ref-type="ref"} Iodothyronine deiodinase 2 has a \~500‐fold higher affinity for T4 than DIO1.[14](#cas14100-bib-0014){ref-type="ref"} Given the tissue distribution and enzymatic property, DIO2 is currently regarded as the central DIO that activates TH in the body.[12](#cas14100-bib-0012){ref-type="ref"}

![Elevated expression of *Dio2* in intestinal polyps of *Apc* ^Δ716^ mice. A, Schematic diagram of deiodination of thyroxine (T4). DIO, iodothryonine deiodinase; I, iodine atom; rT3, 3,3′,5′‐triiodo‐l‐thyronine; T2, 3,3′‐diiodo‐l‐thyronine; T3, 3,3′,5‐triiodo‐l‐thyronine. B, Heat map of DNA microarray data of small intestinal (SI) normal mucosa and polyps (n = 3, each group). Colors were coded according to *Z*‐scored signal intensity. *Thra*, thyroid hormone receptor, α; *Thrb*, thyroid hormone receptor, β. C, Expression of *Dio2* in normal and polyp tissues from *Apc* ^Δ716^ mice analyzed by real‐time RT‐PCR. CN, normal colon; CP, colonic polyps; SN, normal small intestine; SP, small intestinal polyps. SN and SP, n = 7, *P*‐value = 9.56 × 10^−5^ by paired 2‐tailed *t* test on log‐transformed data. CN and CP, n = 8, *P*‐value = 8.99 × 10^−6^. \*\*\**P* \< .001 compared with SN or CN](CAS-110-2520-g001){#cas14100-fig-0001}

A growing body of evidence indicates altered expression of DIOs in several types of cancers[13](#cas14100-bib-0013){ref-type="ref"} and many cancer cell lines, including those from CRC highly express DIO3.[15](#cas14100-bib-0015){ref-type="ref"}, [16](#cas14100-bib-0016){ref-type="ref"}, [17](#cas14100-bib-0017){ref-type="ref"} An in vitro study showed that inhibition of Wnt signaling, the key initial step for CRC development,[18](#cas14100-bib-0018){ref-type="ref"} reduced DIO3 levels and induced DIO2 levels in Caco‐2 cells.[15](#cas14100-bib-0015){ref-type="ref"} Although these results suggest the involvement of DIOs in carcinogenesis, their roles in CRC development remain poorly understood.

Here we report elevated expression of DIO2 in the stroma of intestinal tumors in *Apc* ^Δ716^ mice, a genetically engineered mouse model for familial adenomatous polyposis and the early stage of sporadic CRC.[19](#cas14100-bib-0019){ref-type="ref"} Our study also shows that inhibition of DIOs suppresses the growth of intestinal tumors in *Apc* ^Δ716^ mice and prolongs their survival, accompanied by reduced angiogenesis in the tumor microenvironment.

2. MATERIALS AND METHODS {#cas14100-sec-0002}
========================

2.1. Animals and drug treatments {#cas14100-sec-0003}
--------------------------------

The construction of *Apc* ^Δ716^ mouse strain was described previously.[19](#cas14100-bib-0019){ref-type="ref"} For inhibition of deiodinases, *Apc* ^Δ716^ mice at 12 weeks of age were given 0.02% (w/v) IOP (CAS 96‐83‐3; Tokyo Chemical Industry, Tokyo, Japan) in drinking water. For the survival assay, IOP treatment was started at 8 weeks of age. For chemical thyroidectomy, *Apc* ^Δ716^ mice at 12 weeks of age were given drinking water containing 0.02% (w/v) MMI (CAS 60‐56‐0; Sigma) and 1% (w/v) PP (CAS 7778‐74‐7; Sigma). All animal experiments were undertaken according to the protocols approved by the Animal Care and Use Committee of Aichi Cancer Center Research Institute (Nagoya, Japan).

2.2. Histological analysis and IHC {#cas14100-sec-0004}
----------------------------------

For histological analysis and IHC, we used 5‐μm sections of formalin‐fixed paraffin‐embedded mouse tissue samples and human colon carcinoma tissue microarray (Cat No. CO703a; US Biomax). For BrdU staining, we injected BrdU (12 mg/kg; Sigma) and 5‐fluoro‐2′‐deoxyuridine (1.2 mg/kg; Sigma) into the peritoneal cavity of mice 1 hour before analysis, and prepared paraformaldehyde‐fixed paraffin‐embedded samples. The following primary Abs were used for IHC: anti‐CD34 Ab (clone MEC 14.7; BioLegend), anti‐BrdU Ab (clone BU1/75; Bio‐Rad), anti‐vimentin Ab (clone D21H3; Cell Signaling Technology), anti‐COX‐2 Ab (clone D5H5; Cell Signaling Technology). To detect primary Abs, VECTASTAIN Elite ABC kit and ImmPACT DAB system (Vector Laboratories) were used according to the manufacturer\'s protocols. All clinical tissues on the tissue microarray were sampled under the highest ethical standards and US HIPAA audit protocols (US Biomax).

2.3. In situ hybridization {#cas14100-sec-0005}
--------------------------

Five micrometer‐thick sections from formalin‐fixed paraffin‐embedded mouse tissue samples and clinical colon carcinoma tissue microarrays (Cat No. CO703a; US Biomax) were subjected to in situ hybridization procedure. RNAscope in situ hybridization probes for murine *Dio2* mRNA (Cat No. 479331) and human *DIO2* mRNA (Cat No. 562211) were synthesized by Advanced Cell Diagnostics USA. The probes on the slides were detected with RNAscope 2.0 HD Detection Kit‐BROWN (Advanced Cell Diagnostics) for mouse samples, and RNAscope 2.5 HD Detection Kit‐BROWN for human samples, according to the manufacturer\'s protocol.

2.4. DNA microarray and real‐time RT‐PCR analysis {#cas14100-sec-0006}
-------------------------------------------------

Freshly dissected intestinal tumors and normal intestinal tissues were immersed in RNAlater solution (Thermo Fisher Scientific) overnight and stored frozen at −80°C until further processing. The epithelial and stromal samples were prepared by microdissecting 7‐μm‐thick fresh frozen sections on polyethylene naphthalate membrane slides using an [LMD7000](LMD7000) laser microdissection microscope (Leica Microsystems). Total RNA was isolated using an RNeasy Mini Kit (Qiagen) with on‐column RNase‐free DNase I (Qiagen) treatment. A High‐Capacity cDNA Reverse Transcription Kit (Life Technologies) was used for synthesis of complementary DNA from total RNA. DNA microarray analysis was carried out using an Agilent Technologies platform (Mouse GE 4 × 44K v2 Microarray). Real‐time PCR reactions were carried out using a 7500 Fast Real‐Time PCR system (Applied Biosystems, Life Technologies). The mRNA levels of *Dio2, Vimentin*, and *Gapdh* were quantified with the TaqMan Gene Expression assays (Mm00515664_m1, Mm01333430_m1, and Mm99999915_g1, respectively) from Applied Biosystems. *Gapdh* was used as an internal control to normalize the expression levels of *Dio2* and *Vimentin* by the comparative 2^−ΔΔCT^ method.[20](#cas14100-bib-0020){ref-type="ref"}

2.5. Data and statistical analyses {#cas14100-sec-0007}
----------------------------------

Data and statistical analyses were undertaken using R (version 3.4.3; R Foundation for Statistical Computing). The single‐channel Agilent DNA microarray raw data were preprocessed using the LIMMA package,[21](#cas14100-bib-0021){ref-type="ref"} and differential expression analysis was carried out using the Rank products package.[22](#cas14100-bib-0022){ref-type="ref"} The HTSeq‐FKPM‐UQ datasets of GDC TCGA Colon Cancer (COAD) and GDC TCGA Rectal Cancer (READ) were obtained from GDC Xena Hub run by the UC Santa Cruz Genomics Institute (https://xena.ucsc.edu). Recurrent and metastatic tumor datasets were excluded from these datasets. Enrichment analysis was undertaken using Metascape (http://metascape.org).[23](#cas14100-bib-0023){ref-type="ref"} Values of *P* \< .05 were considered significant.

3. RESULTS {#cas14100-sec-0008}
==========

3.1. *Dio2* is highly expressed in stromal regions of intestinal polyps in *Apc* ^Δ716^ mice {#cas14100-sec-0009}
--------------------------------------------------------------------------------------------

To identify molecules or signals involved in the tumor microenvironment of small intestinal polyps in *Apc* ^Δ716^ mice, we first carried out differential gene expression analysis using DNA microarray. We found significant upregulation of *Dio2* gene expression in the small intestinal polyps as compared with the normal small intestine tissue with the false discovery rate of 1.48 × 10^−2^ (5.07‐fold change; Figure [1](#cas14100-fig-0001){ref-type="fig"}B). Quantitative PCR analysis showed elevated expression level of *Dio2* both in small intestinal and colonic polyps of *Apc* ^Δ716^ mice (Figure [1](#cas14100-fig-0001){ref-type="fig"}C).

We next explored the site of expression of *Dio2* in the *Apc* ^Δ716^ polyps. Combination of LMD and real‐time RT‐PCR assay revealed almost exclusive expression of *Dio2* mRNA in the stroma of *Apc* ^Δ716^ polyps (Figure [2](#cas14100-fig-0002){ref-type="fig"}A). Successful separation of the epithelial and stromal compartments was confirmed by real‐time RT‐PCR of *Vim* encoding the intermediate filament vimentin, a specific lineage marker for cells of mesenchymal origin (Figure [2](#cas14100-fig-0002){ref-type="fig"}A).

![*Dio2* is expressed in the stromal region of *Apc* ^Δ716^ tumors. A, Expression of *Dio2* in epithelial (epi) and stromal compartment (str) of intestine tissues from *Apc* ^Δ716^ mice analyzed by real‐time RT‐PCR. SN, normal small intestine; SP, small intestinal polyps. Tukey\'s all‐pairwise comparison test was applied. SN epi, SN str, SP epi, and SP str, n = 4, \*\*\**P* \< .001 compared with SN epi. B, In situ hybridization analysis of *Dio2* mRNA in intestine tissues from *Apc* ^Δ716^ mice. Bars: left panels, 200 μm; middle panels, 50 μm; right panels, 50 μm. C, In situ hybridization analysis of *Dio2* mRNA and immunohistochemical analysis of vimentin (Vim) and COX‐2 in intestinal tissues from *Apc* ^Δ716^ mice. Bars: 50 μm](CAS-110-2520-g002){#cas14100-fig-0002}

To validate the LMD results, we undertook in situ hybridization analysis using the small intestinal and colonic tissue sections from *Apc* ^Δ716^ mice. *Dio2* expression in the polyps was predominant in the stromal regions near the luminal border (Figure [2](#cas14100-fig-0002){ref-type="fig"}B). Immunohistochemistry for vimentin using serial sections showed closely overlapped localization of *Dio2* mRNA with that of vimentin (Figure [2](#cas14100-fig-0002){ref-type="fig"}C). Cyclooxygenase‐2 is known to be induced in the tumor microenvironment of *Ap*c^Δ716^ polyps, playing a key role in tumorigenesis of *Ap*c^Δ716^ mice.[24](#cas14100-bib-0024){ref-type="ref"} Immunohistochemistry analysis revealed that the *Dio2*‐positive regions were mostly overlapped with the COX‐2‐positive areas in the tumor stroma (Figure [2](#cas14100-fig-0002){ref-type="fig"}C). Collectively, these results indicate that *Dio2* mRNA is highly expressed in the stromal cells of *Apc* ^Δ716^ polyps.

3.2. Treatment with IOP suppresses polyp formation and prolongs survival in *Apc* ^Δ716^ mice {#cas14100-sec-0010}
---------------------------------------------------------------------------------------------

Iopanoic acid, a classical oral cholecystography agent, contains 3 iodine atoms and potently inhibits DIO1 and DIO2 as shown in Figure [3](#cas14100-fig-0003){ref-type="fig"}A.[25](#cas14100-bib-0025){ref-type="ref"} Iopanoic acid is known to rapidly decrease the serum T3 levels in humans and has been one of the treatment options for thyrotoxicosis in emergency. To address the role of DIO2 in intestinal tumor formation, we treated *Apc* ^Δ716^ mice with 0.02% (w/v) IOP in drinking water (Figure [3](#cas14100-fig-0003){ref-type="fig"}A). Treatment with IOP for 2 months did not deplete TH in the thyroid glands (Figure [3](#cas14100-fig-0003){ref-type="fig"}B) and did not significantly affect the body weight (Figure [3](#cas14100-fig-0003){ref-type="fig"}B) or the basic tissue architecture of the intestinal polyps (Figure [3](#cas14100-fig-0003){ref-type="fig"}C). Importantly, IOP treatment significantly reduced the numbers of total polyps and large‐size polyps (≥1.5 mm) in *Apc* ^Δ716^ mice (Figures [3](#cas14100-fig-0003){ref-type="fig"}D and [S1](#cas14100-sup-0001){ref-type="supplementary-material"}), indicating the role of DIO2 in the growth of intestinal tumors.

![Treatment with the iodothryonine deiodinase inhibitor iopanoic acid (IOP) suppresses intestinal tumor formation and prolongs the survival of *Apc* ^Δ716^ mice. A, Schematic diagram of IOP structure and IOP treatment schedule. B, H&E staining of the thyroid glands from control and IOP‐treated *Apc* ^Δ716^ mice. Box plots of the final body weight of the mice immediately before sampling. Control, 23.9 ± 0.9 g, n = 6; IOP, 23.4 ± 1.2 g, n = 7. Welch 2‐tailed *t* test, *P* = .499; ns, not significant. Bars: 50 μm. C, H&E staining of small intestinal polyp tissues from control and IOP‐treated *Apc* ^Δ716^ mice. Bars: 100 μm. D, Number of total and large‐size polyps (≥1.5 mm) in control (CNT) and IOP‐treated *Apc* ^Δ716^ mice. Total polyps: CNT, 172 ± 34, n = 6; IOP, 122 ± 13, n = 7; Welch 2‐tailed *t* test, *P* = .0136. Large‐size polyps: CNT, 49 ± 17, n = 6; IOP, 23 ± 14, n = 7. *P* = .0170. \**P* \< .05 compared with CNT. E, Kaplan‐Meier survival curves of CNT (n = 7, blue) and IOP‐treated *Apc* ^Δ716^ mice (n = 6, orange). IOP treatment was initiated at 8 wk of age. Median survival time: CNT, 20.3 wk; IOP, 26.0 wk; log rank test, *P* = .0353](CAS-110-2520-g003){#cas14100-fig-0003}

We next examined the survival benefit of IOP treatment on *Apc* ^Δ716^ mice. Thirteen littermate female *Apc* ^Δ716^ mice obtained by in vitro fertilization were randomly allocated to either the control group (7 mice) or IOP treatment group (6 mice) at 8 weeks of age. As expected from the suppressive effect on tumor growth, IOP treatment increased the overall survival of *Apc* ^Δ716^ mice (Figure [3](#cas14100-fig-0003){ref-type="fig"}E). Collectively, these observations indicate that IOP treatment inhibits intestinal tumor formation and confers a survival advantage in *Apc* ^Δ716^ mice.

3.3. Chemically induced hypothyroidism suppresses polyp formation in *Apc* ^Δ716^ mice {#cas14100-sec-0011}
--------------------------------------------------------------------------------------

To confirm further the involvement of TH signaling in intestinal tumor formation in *Apc* ^Δ716^ mice indicated by the IOP experiment, we carried out chemical thyroidectomy using MMI and PP.[26](#cas14100-bib-0026){ref-type="ref"} The former disturbs the iodination of thyroglobulin in the thyroid gland, whereas PP acts as a competitive inhibitor of SLC5A5, a transporter responsible for the uptake of iodine into the thyroid gland.[27](#cas14100-bib-0027){ref-type="ref"} Treatment with a cocktail of 0.02% (w/v) MMI and 1% (w/v) PP in drinking water reproducibly induces hypothyroidism in mice.[26](#cas14100-bib-0026){ref-type="ref"} We confirmed the treatment regimen for 3 months (Figure [4](#cas14100-fig-0004){ref-type="fig"}A) completely depleted TH in the thyroid glands and disrupted the spherical follicles (Figure [4](#cas14100-fig-0004){ref-type="fig"}B), although we did not observe significant changes in general condition or body weight. The treatment with MMI + PP did not cause remarkable changes in tissue components of *Apc* ^Δ716^ polyps (Figure [4](#cas14100-fig-0004){ref-type="fig"}C). However, similar to IOP treatment, the chemical thyroidectomy significantly reduced the numbers of total polyps and those in the large‐size class (≥1.5 mm) in *Apc* ^Δ716^ mice (Figures [4](#cas14100-fig-0004){ref-type="fig"}D and [S1](#cas14100-sup-0001){ref-type="supplementary-material"}).

![Chemical thyroidectomy suppresses intestinal tumor formation. A, Schematic diagram of the schedule of chemical thyroidectomy with 2‐mercapto‐1‐methyl‐imidazole (MMI) and potassium perchlorate (PP). B, H&E staining of thyroid glands 3 mo after chemical thyroidectomy. Body weight of control and MMI + PP‐treated *Apc* ^Δ716^ mice. Box plots of the final body weight of the mice immediately before sampling. Control, 22.8 ± 1.6 g, n = 9; MMI + PP, 22.7 ± 2.3 g, n = 9. Welch 2‐tailed *t* test, *P* = 0.897; ns, not significant. Bars: 50 μm. C, H&E staining of polyp tissues from control (CNT) and MMI + PP‐treated *Apc* ^Δ716^ mice. Bars: 100 μm. D, Number of total and large‐size polyps (≥1.5 mm) in CNT and MMI + PP‐treated *Apc* ^Δ716^ mice. Total polyps: CNT, 174 ± 49, n = 9; MMI + PP, 97 ± 35, n = 9; Welch 2‐tailed *t* test, *P* = .00178. Large‐size polyps: CNT, 63 ± 37, n = 9; MMI + PP, 12 ± 8, n = 9. *P* = .00317. \*\**P* \< .01 compared with CNT](CAS-110-2520-g004){#cas14100-fig-0004}

3.4. Iodothyronine deiodinase 2 induces tumor cell proliferation and stimulates angiogenesis downstream of COX‐2 {#cas14100-sec-0012}
----------------------------------------------------------------------------------------------------------------

To gain insights into the mechanism by which the inhibition of TH signaling or DIO2 suppresses the growth of *Apc* ^Δ716^ polyps, we next examined the proliferation rate of tumor epithelial cells. Treatment with IOP or with MMI + PP significantly decreased the BrdU labeling index in the polyp regions of *Apc* ^Δ716^ mice (Figure [5](#cas14100-fig-0005){ref-type="fig"}A,B). The MMI + PP treatment decreased the BrdU index in the normal crypt epithelial cells as well, suggesting that the proliferation of normal intestinal epithelial cells is also dependent on TH (Figure [5](#cas14100-fig-0005){ref-type="fig"}B). Proliferation of tumor cells in vivo is controlled not only by growth‐regulating signaling pathways, but also by angiogenesis in the microenvironment. We thus determined the MVD index in the polyps using IHC for CD34, an endothelial cell marker. Both the IOP treatment and MMI + PP treatment significantly decreased the MVD index of the polyps as compared with vehicle treatments (Figure [5](#cas14100-fig-0005){ref-type="fig"}C,D). We found colocalization of *Dio2* mRNA and COX‐2 protein in the microenvironment of *Apc* ^Δ716^ polyps (Figure [2](#cas14100-fig-0002){ref-type="fig"}C). Because COX‐2 was shown to play a key role in tumor formation in *Apc* ^Δ716^ mice by inducing angiogenesis,[28](#cas14100-bib-0028){ref-type="ref"} we examined the possible involvement of COX‐2 in DIO2 expression in *Apc* ^Δ716^ polyps. As shown in Figure [5](#cas14100-fig-0005){ref-type="fig"}E, 3‐day treatment with the COX‐2 inhibitor meloxicam greatly reduced the level of *Dio2* mRNA in *Apc* ^Δ716^ polyps, indicating that DIO2 acts downstream of COX‐2 in the intestinal tumor microenvironment.

![Deiodinase inhibition or chemical thyroidectomy reduces tumor cell proliferation and angiogenesis downstream of COX‐2 in *Apc* ^Δ716^ polyps. A, BrdU labeling index (%) of intestinal polyps (left) and normal intestinal crypts (right) from control (CNT) and iopanoic acid (IOP)‐treated *Apc* ^Δ716^ mice. Polyps: CNT, 51.4 ± 10.5%, n = 4; IOP, 36.8 ± 13.1%, n = 4. Welch 2‐tailed *t* test, *P* = 2.2 × 10^−16^. Normal crypts: CNT, 33.7 ± 9.1%, n = 4; IOP, 30.8 ± 10.1%, n = 4. *P* = 4.32 × 10^−2^. \**P* \< .05, \*\*\**P* \< .001 compared with CNT. B, BrdU labeling index (%) of intestinal polyps (left) and normal intestinal crypts (right) from CNT and 2‐mercapto‐1‐methyl‐imidazole and potassium perchlorate (MMI + PP)‐treated *Apc* ^Δ716^ mice. Polyps: CNT, 53.3 ± 11.5%, n = 4; MMI + PP, 39.5 ± 11.7%, n = 4. Welch 2‐tailed *t* test, *P* = 1.17 × 10^−14^. Normal crypts: CNT, 32.8 ± 7.6%, n = 4; MMI + PP, 25.3 ± 7.1%, n = 4. *P* = 4.82 × 10^−8^. \*\*\**P* \< .001 compared with control. C, Microvessel density (MVD) index of intestinal polyps from control and IOP‐treated *Apc* ^Δ716^ mice. Control, 31.2 ± 9.3%, n = 4; IOP, 17.1 ± 7.8%, n = 5. *P* = 6.60 × 10^−7^. \*\*\**P* \< .001 compared with CNT. D, MVD index of intestinal polyps from control and MMI + PP‐treated *Apc* ^Δ716^ mice. CNT, 29.1 ± 9.5%, n = 4; MMI + PP, 21.2 ± 10.1%, n = 4. *P* = 8.08 × 10^−5^. \*\*\**P* \< .001 compared with CNT. E, Real‐time RT‐PCR analysis for *Dio2* mRNA expression level in intestinal polyps from CNT and meloxicam‐treated *Apc* ^Δ716^ mice. CNT, n = 11; meloxicam, n = 8. *P* = 7.38 × 10^−3^ by paired 2‐tailed *t* test on log‐transformed data. \*\**P* \< .01 compared with CNT](CAS-110-2520-g005){#cas14100-fig-0005}

3.5. *DIO2* expression is increased in clinical samples of CRC {#cas14100-sec-0013}
--------------------------------------------------------------

To address the expression profile of *DIO2* in human CRC, we analyzed RNA sequencing datasets for colon and rectal cancer in TCGA database.[18](#cas14100-bib-0018){ref-type="ref"} We found significant upregulation of *DIO2* mRNA levels in primary tumor tissues of colon cancer as compared with the normal colon tissue (Figure [6](#cas14100-fig-0006){ref-type="fig"}A). The result is consistent with data provided in a recent review.[29](#cas14100-bib-0029){ref-type="ref"} Rectal cancer gene expression data also showed upregulation of *DIO2* mRNA in primary rectal tumor tissues (Figure [6](#cas14100-fig-0006){ref-type="fig"}A) as compared with the normal rectal tissue. In situ hybridization for *DIO2* using human colon cancer tissue samples indicated that *DIO2* expression was restricted to the stromal region of colon cancer tissues (Figure [6](#cas14100-fig-0006){ref-type="fig"}B). Collectively, these results suggest the expression pattern of *DIO2* in human CRC is highly similar to that of *Dio2* in *Apc* ^Δ716^ tumors (Figure [2](#cas14100-fig-0002){ref-type="fig"}C). Taken together, these data indicate that tumor stromal cells, rather than tumor epithelial cells, highly express *DIO2* in CRC tissues.

![*DIO2* expression is increased in the clinical samples of colorectal cancer. A, RNA sequencing analysis for *DIO2* expression in colon and rectal cancer obtained from The Cancer Genome Atlas (TCGA) database (COAD and READ datasets). Unit of *Y*‐axis: log2(fpkm‐uq + 1). CC, colon cancer tissues; Nrm, normal colon or rectal tissue; RC, rectal cancer tissues. Normal colons, n = 41; colon cancers, n = 469, *P* = 2.2 × 10^−16^ by Welch 2‐tailed *t* test; normal rectums, n = 10; rectal cancers, n = 166, *P* = 3.35 × 10^−9^ by Welch 2‐tailed *t* test. \*\*\**P* \< .001 compared with the normal colonic or rectal tissue. B, In situ hybridization analysis of *DIO2* mRNA in colon cancer clinical samples with hematoxylin counterstaining. Colon Cancer 1, T3N0M0, IIA; Colon Cancer 2, T4N1M0, Stage IIIB. Bars: left panels, 50 μm; right panels, 10 μm. C, Spearman\'s correlation coefficient (ρ) between expression levels of *DIO2* and other genes in TCGA COAD (colon cancer) and TCGA READ (rectal cancer) datasets. *X* axis, ρ calculated from COAD;*Y*‐axis, ρ calculated from READ; dashed lines, ρ = 0.6; red circles, selected 195 genes. Two‐dimensional kernel density estimation (KDE); dashed lines, ρ = 0.0 and ρ = 0.6. D, Enrichment analysis of selected 195 genes that were highly coexpressed with *DIO2* mRNA in colon and rectal cancer tissues. Red bars, clustering enrichment terms related to ECM. E, Spearman\'s correlation matrix heat map between *DIO2* and tumor endothelial markers (*ANTXR1*,*CD248*,*ADGRA2*, and *PLXDC1*) and COX‐2 in TCGA COAD and TCGA READ datasets. F, Immunohistochemical analysis of COX‐2 in colon cancer clinical samples with hematoxylin counterstaining. COX‐2 is expressed both in the stromal and epithelial regions. Colon Cancer 1, T3N0M0, IIA; Colon Cancer 2, T4N1M0, Stage IIIB. Bars: 50 μm](CAS-110-2520-g006){#cas14100-fig-0006}

We next explored genes that were highly coexpressed with *DIO2* in CRC tissues. We first calculated Spearman\'s correlation coefficient (ρ) between the expression levels of *DIO2* and other genes in TCGA COAD (colon cancer) as well as in TCGA READ (rectal cancer) datasets. Two‐dimensional mapping of the pairing coefficient of each gene showed a strong positive correlation (Pearson\'s correlation coefficient; r = 0.845, 95% confident interval, 0.842‐0.848) and 2‐D kernel density estimation revealed the points were concentrated near the origin and formed a unimodal distribution (Figure [6](#cas14100-fig-0006){ref-type="fig"}C). We then selected 195 genes that showed highly positive correlated expression with *DIO2* in both the sets (ρ ≥ 0.6). Enrichment analysis of those genes showed high correlation of *DIO2* expression with that of the ensemble of ECM genes (Figure [6](#cas14100-fig-0006){ref-type="fig"}D; red bars), suggesting a close association of *DIO2* expression with the stromal compartment of CRC tissues. Intriguingly, we found *ANTXR1* was one of the most strongly correlated genes with *DIO2* in CRC tissues (Figure [6](#cas14100-fig-0006){ref-type="fig"}E). *ANTXR1* was initially identified as one of a number of genes involved in colon tumor angiogenesis and was thus named *tumor endothelial marker 8* (*TEM8*).[30](#cas14100-bib-0030){ref-type="ref"}, [31](#cas14100-bib-0031){ref-type="ref"} The correlation analysis also suggested that *DIO2* mRNA was highly coexpressed with other tumor‐specific endothelial marker genes (*CD248*,*ADGRA2*, and *PLXDC1*; Figure [6](#cas14100-fig-0006){ref-type="fig"}E).

Our analysis of *Apc* ^Δ716^ tumors indicated a close anatomical and functional relationship between Dio2 and COX‐2 expression (Figures [2](#cas14100-fig-0002){ref-type="fig"}C and [5](#cas14100-fig-0005){ref-type="fig"}E). We thus examined an association between DIO2 and COX‐2 in human clinical samples. Analysis of TCGA data showed that *COX‐2* expression was not highly correlated with *DIO2* (Figure [6](#cas14100-fig-0006){ref-type="fig"}E). Immunohistochemistry analysis revealed that COX‐2 was expressed both in the stromal and epithelial regions of human colon cancer samples (Figure [6](#cas14100-fig-0006){ref-type="fig"}F). The weaker correlation between *COX‐2* and *DIO2* in human CRC could be explained by strong epithelial expression of COX‐2 in advanced human CRC.

4. DISCUSSION {#cas14100-sec-0014}
=============

This study showed that DIO2 promotes intestinal tumor formation in *Apc* ^Δ716^ mice. Treatment with IOP, a classical radiograph contrast agent that acts as a DIO2 inhibitor, suppressed intestinal tumor formation in *Apc* ^Δ716^ mice and increased their survival (Figure [3](#cas14100-fig-0003){ref-type="fig"}D,E). Iodothyronine deiodinase 2 serves as a local activator of TH signaling by deiodinating T4 and thereby converting it into bioactive T3 (Figure [1](#cas14100-fig-0001){ref-type="fig"}A). Consistent with the TH‐activating function of DIO2, the chemical thyroidectomy also suppressed the growth of *Apc* ^Δ716^ polyps (Figure [4](#cas14100-fig-0004){ref-type="fig"}D). We found almost exclusive expression of *Dio2* mRNA in the stroma compartment of intestinal tumors in *Apc* ^Δ716^ polyps (Figure [2](#cas14100-fig-0002){ref-type="fig"}A). Although it is not clear which cell types in the tumor stroma express DIO2, partly due to the lack of a reliable Ab that can be used for immunochemical or flow cytometric analysis of DIO2 expression, in situ hybridization analysis for *Dio2* and immunostaining for COX‐2 in serial sections suggest that DIO2 is most likely expressed by fibroblasts and/or vascular endothelial cells (Figure [2](#cas14100-fig-0002){ref-type="fig"}C). Furthermore, we were able to show that treatment with the COX‐2 inhibitor meloxicam reduced the *Dio2* level in *Apc* ^Δ716^ tumors (Figure [5](#cas14100-fig-0005){ref-type="fig"}E). These findings are consistent with the established role of COX‐2 and prostaglandin E2 in promoting intestinal tumorigenesis by enhancing angiogenesis.[28](#cas14100-bib-0028){ref-type="ref"} Seno et al[28](#cas14100-bib-0028){ref-type="ref"} also showed that the angiogenic switch by COX‐2 was mediated by the EP2 receptor, which is expressed by both vascular endothelial cells and fibroblasts. Collectively, our data indicate that DIO2 is a downstream effector of COX‐2 in the microenvironment of *Apc* ^Δ716^ polyps. Further studies are needed to elucidate the molecular mechanism by which COX‐2 induces DIO2 expression.

Consistent with the results obtained from the mouse model, we found overexpression of *DIO2* mRNA in human CRCs using TCGA database and provided in situ hybridization analysis data that indicate the expression of *DIO2* in the stromal component of CRC tissues (Figure [6](#cas14100-fig-0006){ref-type="fig"}). Previous reports showed both tumor‐promoting and tumor‐suppressive roles of TH signaling in CRC,[32](#cas14100-bib-0032){ref-type="ref"} but their mechanistic studies mostly dealt with TH signaling in cancer epithelial cells and not in the tumor stromal cells. Specifically, TRα1 was shown to activate Wnt signaling in intestinal epithelial cells by directly inducing transcription of *CTNNB1* gene encoding β‐catenin and the *sFRP2* gene encoding a Frizzled‐related protein.[8](#cas14100-bib-0008){ref-type="ref"}, [9](#cas14100-bib-0009){ref-type="ref"} The same group further showed that transgenic expression of TRα1 in *Apc* ^+/1638N^ mice enhances intestinal tumor formation[33](#cas14100-bib-0033){ref-type="ref"} and that knockdown of TRα1 suppressed proliferation of Caco‐2 cells. In contrast, Dentice et al[15](#cas14100-bib-0015){ref-type="ref"} suggested the growth‐suppressive roles of TH signaling in CRC cells. In the study, they showed that expression levels of DIO3, a TH inactivator, were elevated in clinical samples of colonic adenomas and CRC compared to normal colon tissues, and that DIO3 knockdown suppressed proliferation of CRC cells.[15](#cas14100-bib-0015){ref-type="ref"} They also showed nearly restricted expression of DIO3 in the epithelial compartment of CRC,[15](#cas14100-bib-0015){ref-type="ref"} in contrast to the almost exclusive expression of DIO2, a TH activator, in the stroma of *Apc* ^Δ716^ tumors and human CRC samples (Figures [2](#cas14100-fig-0002){ref-type="fig"}C and [6](#cas14100-fig-0006){ref-type="fig"}B). An apparently paradoxical observation that both the activator and inhibitor of TH are overexpressed in CRC could be explained by their differential expression in the epithelial and stromal components. Further investigation will be required to fully understand the precise roles of deiodinases and TH signaling in tumor epithelial and stromal cells of CRC.

Although altered expression of DIO2 has been reported in other types of malignancies, including brain tumors and thyroid cancer,[29](#cas14100-bib-0029){ref-type="ref"} the role of stromal DIO2 in tumor angiogenesis has not been documented so far. Thyroid hormone signaling itself, however, has been implicated in tumor angiogenesis through binding of the prohormone T4 to integrin αvβ3 on the surface of endothelial and vascular smooth muscle cells.[34](#cas14100-bib-0034){ref-type="ref"} Our current study indicates another mechanism by which TH signaling is involved in tumor angiogenesis. It is thus possible that the antiangiogenic effect of chemical thyroidectomy by MMI + PP was partly mediated by the T4/integrin αvβ3 axis.

Here we have found that DIO2 is highly expressed in the stroma of intestinal tumors in *Apc* ^Δ716^ mice as well as in clinical samples of CRC. Inhibition of deiodinases or chemical thyroidectomy significantly suppressed tumor formation in *Apc* ^Δ716^ mice accompanied by reduced angiogenesis. The results indicate that DIO2‐regulated TH signaling in the tumor microenvironment is essential for intestinal tumor growth and that DIO2 can be a therapeutic target.
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